Oklahoma City, OKNCT02013336Now EnrollingIRB Ready

Recurrent or Refractory Solid Tumors Clinical Trial in Oklahoma City, OK

Access cutting-edge recurrent or refractory solid tumors treatment through this phase 1 clinical trial at a research site in Oklahoma City. Study-provided care at no cost to qualified participants.

Sponsored by South Plains Oncology Consortium

Quick Self-Assessment

See if you qualify for this Oklahoma City location

Preparing your pre-screening questions…

Expert Care in Oklahoma City

Access recurrent or refractory solid tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related recurrent or refractory solid tumors treatment provided free

Apply for This Oklahoma City Location

Check if you qualify for this recurrent or refractory solid tumors clinical trial in Oklahoma City, OK

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Oklahoma City

    Convenient for OK residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Oklahoma City site if eligible
  4. 4Begin participation

About This Recurrent or Refractory Solid Tumors Study in Oklahoma City

This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.

Sponsor: South Plains Oncology Consortium

Who Can Participate

Inclusion Criteria

Histologically or cytologically-confirmed Ewing sarcoma, rhabdomyosarcoma, neuroblastoma, or osteosarcoma
Disease progression after prior therapy in locally advanced or metastatic setting
Measurable or evaluable disease based on the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria
Age 12 months to \<21 years
Adequate bone marrow reserves, hepatic function, and renal function
Recovered from effects of any prior surgery or cancer therapy
Patients 18 years or older will provide written consent. A parent or legal guardian of a patient \<18 years of age will provide informed consent and patients 11 to 18 years of age will provide written assent or as per participating institutional policy.

Exclusion Criteria

Clinically significant gastrointestinal disorders
NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure
Active infection or unexplained fever
Known hypersensitivity to any of the components of MM-398 or other liposomal products
Recent Investigational therapy
Pregnant or breast feeding; females of child-bearing potential must test negative for pregnancy at the time of enrollment

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Oklahoma City?

Yes, this clinical trial (NCT02013336) has an active research site in Oklahoma City, OK that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Recurrent or Refractory Solid Tumors Treatment Options in Oklahoma City, OK

If you're searching for recurrent or refractory solid tumors treatment options in Oklahoma City, OK, this clinical trial (NCT02013336) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Oklahoma City research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced recurrent or refractory solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all recurrent or refractory solid tumors clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Oklahoma City, OK

See all advanced solid tumors clinical trials recruiting in Oklahoma City — not just this study.

Browse Advanced Solid Tumors Trials in Oklahoma City →

Browse More Trials by Condition

Advanced Solid Tumors TrialsRheumatoid Arthritis TrialsAll Conditions →

Ready to Join in Oklahoma City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Oklahoma City, OK